Canada Retinal Disorder Treatment Market Insight
Published: 19 May 2026 | Report Format: Electronic (PDF)
The Canada retinal disorder treatment market size is growing at a 10.65%CAGR, driven by the increasing demand for advanced ophthalmic therapies across Canada.
Canada Retinal Disorder Treatment Market Insights Forecasts to 2035
- The Canada Retinal Disorder Treatment Market Size Was Estimated at USD571.3 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around10.65%from 2025 to 2035
- The Canada Retinal Disorder Treatment Market Size is Expected to Reach USD 1572.1 Million by 2035
Notable Insights for Canada Retinal Disorder Treatment Market
- By type of disorder, age-related macular degeneration was the market leader in the Canada retinal disorder treatment market in 2025, accounting for nearly 36-37%, owing to the increasing number of instances of age-related retinal problems and visual impairments.
- By treatment type, anti-VEGF emerged as the market leader in the Canada retinal disorder treatment market with nearly 42-43% share in 2025 due to the extensive application of biological injections for managing retinal vascular diseases.
- Health Canada regulates and approves all ophthalmic medicines, biological products, retinal implant surgeries, and medical devices in the country, as well as any other retinal disorder treatment therapies, under its stringent framework.
Download the eBook (ToC)
- The Canadian Institute of Health Research supports and develops healthcare innovations and technologies in the field of ophthalmology and retina disorders, which help improve the healthcare sector of the country.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the Canada retinal disorder treatment market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in Canada Retinal Disorder Treatment Market
- F. Hoffmann-La Roche Ltd.
- Regeneron Pharmaceuticals, Inc.
- Novartis AG
- Bayer AG
- AbbVie Inc.
- Alimera Sciences, Inc.
- Bausch + Lomb Corporation
- Apellis Pharmaceuticals, Inc.
- Johnson & Johnson Vision
- Carl Zeiss Meditec AG
Recent Developments:
- In March 2025, Canada retinal disorder treatment market grew on rising anti-VEGF biologics adoption and long-acting ophthalmic drugs, with over $1.6B North American investments driving AMD and diabetic retinopathy treatment innovation and improved vision outcomes nationwide.
Market Segmentation:
Canada Retinal Disorder Treatment Market, By Disorder Type
- Age-Related Macular Degeneration
- Diabetic Retinopathy
- Retinal Vein Occlusion
- Retinal Detachment
- Others
Canada Retinal Disorder Treatment Market, By Treatment Type
- Anti-VEGF Therapy
- Laser Therapy
- Corticosteroid Therapy
- Vitrectomy Surgery
- Others
Canada Retinal Disorder Treatment Market, By Drug Type
- Biologics
- Corticosteroids
- Gene Therapies
- Others
Canada Retinal Disorder Treatment Market, By End User
- Hospitals
- Ophthalmology Clinics
- Ambulatory Surgical Centers
- Others
Expert Views:
The Canada retinal disorder treatment market is poised to experience strong future growth on account of the ongoing evolution of the country’s eye care sector due to aging populations, biologics, and advances in precision ophthalmology technologies. The increased need for early detection and treatment of retinal disorders through non-invasive and personalized treatments will be key drivers of market growth.
Author: Govind and Krishna By Spherical Insights and Consulting